Chaitanya Case Study Write -4
docx
keyboard_arrow_up
School
Northeastern University *
*We aren’t endorsed by this school
Course
6463
Subject
Health Science
Date
Dec 6, 2023
Type
docx
Pages
8
Uploaded by DoctorTankPanther28
Case Study Write-Up – 4
Chasing Polio Eradication: Vaccine Development
1.
In 2-3 paragraphs please explain how poliovirus is transmitted –additionally:
A.
Poliovirus, the causative agent of poliomyelitis, is primarily transmitted through the fecal-
oral route. This means that the virus is shed in the feces of an infected person and can be
ingested by another person through contaminated food, water, or hands. This is particularly
common in areas with poor sanitation and hygiene practices.
In addition to the fecal-oral route, poliovirus can also be transmitted through respiratory
droplets, although this is less common. This can occur when an infected person coughs or
sneezes, releasing droplets into the air that can be inhaled by another person. It's important to
note that poliovirus is highly contagious and can spread rapidly in a susceptible population.
Vaccination is the most effective way to prevent poliovirus transmission.
a.Why was a bivalent oral polio vaccine (bOPV) chosen as a key strategic tool?
A. The Bivalent Oral Polio Vaccine (bOPV) was chosen as a key strategic tool in the fight
against polio for several reasons:
1.
Effectiveness against multiple strains
:
bOPV is effective against both Poliovirus type
1 and type 3. This makes it a versatile tool in combating polio, as it can protect
against multiple strains of the virus.
2.
Ease of administration: The oral vaccine is easy to administer, especially in large-
scale immunization campaigns. It does not require trained healthcare professionals for
administration, which makes it ideal for use in areas with limited healthcare
infrastructure.
3.
Cost-effectiveness: bOPV is relatively inexpensive to produce and distribute, making
it a cost-effective solution for large-scale immunization programs.
4.
Induces strong immunity: The oral vaccine induces a strong immune response in the
gut, the primary site of poliovirus multiplication, providing robust protection against
the disease.
5.
Community protection: The vaccine-virus can spread from the vaccinated individual
to others in the community, thereby indirectly vaccinating and protecting
unvaccinated individuals.
b.What were the key steps in the development of bOPV?
a. The bivalent Oral Polio Vaccine (bOPV) is a significant development in the fight against
polio. It targets two of the three poliovirus serotypes: type 1 and type 3. The key steps in the
development of bOPV are as follows:
1.
Identification of the Need
:
The first step was recognizing the need for a more
effective vaccine. The trivalent OPV (tOPV) was less effective against type 1 and type
3 polioviruses compared to the monovalent OPV (mOPV).
2.
Research and Development
:
Extensive research was conducted to develop a vaccine
that could effectively immunize against both type 1 and type 3 polioviruses. This
involved laboratory testing and clinical trials.
3.
Clinical Trials
:
The vaccine underwent rigorous clinical trials to ensure its safety and
efficacy. The trials showed that bOPV was more effective than tOPV in providing
immunity against type 1 and type 3 polioviruses.
4.
Approval and Licensing: After successful clinical trials, the vaccine was approved by
regulatory authorities. The World Health Organization (WHO) prequalified bOPV for
global use in 2009.
5.
Mass Production and Distribution
:
Once approved, the vaccine was mass-produced
and distributed globally, particularly in regions with ongoing polio transmission.
6.
Monitoring and Evaluation
:
Post-implementation, the effectiveness of the vaccine is
continually monitored and evaluated. This helps in identifying any potential issues
and making necessary adjustments
c
.Who were the key stakeholders involved in both bOPV development and
implementation?
The development and implementation of bivalent oral polio vaccine (bOPV) involved several
key stakeholders. These stakeholders played crucial roles in various stages of the process,
from research and development to distribution and administration of the vaccine.
Stakeholders in bOPV Development
1.
World Health Organization (WHO): The WHO played a significant role in the
development of bOPV. They provided technical guidance and support, and also
facilitated international collaboration.
2.
Research Institutions and Universities: Various research institutions and universities
were involved in the scientific research and development of the vaccine.
3.
Pharmaceutical Companies: Companies like GlaxoSmithKline, Sanofi Pasteur, and
others were involved in the production and testing of the vaccine.
Stakeholders in bOPV Implementation
1.
World Health Organization (WHO): The WHO also played a key role in the
implementation of the bOPV. They coordinated global efforts, provided guidelines for
vaccine administration, and monitored the progress of polio eradication efforts.
2.
National Governments: National governments were responsible for implementing the
vaccination programs in their respective countries. They worked in collaboration with
the WHO and other stakeholders to ensure the vaccine reached all children.
3.
Non-Governmental Organizations (NGOs
)
: NGOs like the Bill and Melinda Gates
Foundation, Rotary International, and others provided funding and support for the
implementation of the vaccination programs.
4.
Healthcare Providers: Healthcare providers were on the front lines, administering the
vaccine to children.
5.
Communities and Parents: Communities and parents are also key stakeholders as they
are the recipients of the vaccine and play a crucial role in ensuring children receive
the vaccine.
2.How did the development of the bOPV align with evolving programmatic needs? What
were the vaccination tools available to the Global Polio Eradication Initiative (GPEI) prior to
bOPV? Why were new strategies required for the polio eradication program in remaining
endemic countries? What was the programmatic impact of the bOPV introduction? in
paragraphs
A.Development of bOPV and Evolving Programmatic Needs
The development of bivalent oral polio vaccine (bOPV) was a significant step in the Global
Polio Eradication Initiative (GPEI). The bOPV was designed to address the evolving
programmatic needs of the initiative, particularly the need to target multiple serotypes of the
poliovirus simultaneously. The bOPV targets both type 1 and type 3 polioviruses, which were
the most prevalent and virulent types remaining.
Before the introduction of bOPV, the
GPEI
primarily used two types of vaccines:
Trivalent oral polio vaccine (tOPV
):
This vaccine targeted all three types of
poliovirus. However, it was less effective against types 1 and 3 compared to bOPV.
Monovalent oral polio vaccines (mOPVs): These vaccines targeted a single type of
poliovirus. They were more effective than tOPV but required separate administration
for each type.
New strategies were required for the polio eradication program in remaining endemic
countries due to several reasons:
Vaccine-derived polioviruses (VDPVs): The use of tOPV led to the emergence of
VDPVs, particularly in areas with low vaccination coverage.
Vaccine effectiveness: The effectiveness of tOPV against types 1 and 3 was lower
than desired, necessitating a more potent vaccine.
Logistical challenges: The use of mOPVs posed logistical challenges due to the need
for separate administration for each type.
The introduction of bOPV had a significant programmatic impact:
Improved effectiveness
:
bOPV proved to be more effective against types 1 and 3
polioviruses compared to tOPV.
Reduced VDPVs: The use of bOPV led to a reduction in the emergence of VDPVs.
Simplified logistics: The bOPV simplified vaccination campaigns by targeting two
types of poliovirus with a single vaccine.
In conclusion, the development and introduction of bOPV was a critical step in the GPEI's
efforts to eradicate polio, addressing several programmatic challenges and improving the
effectiveness of vaccination campaigns.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
3.What were the key stages from a product lifecycle perspective that had to be addressed in
the development of bOPV?
A. The development of bivalent oral polio vaccine (bOPV) involved several key stages from
a product lifecycle perspective. These stages are crucial in ensuring the safety, efficacy, and
quality of the vaccine.
1. Research and Development
This is the initial stage where the concept of the vaccine is developed. It involves extensive
laboratory research and testing to identify potential vaccine candidates.
2. Preclinical Testing
Before the vaccine is tested on humans, it undergoes preclinical testing in the lab and on
animals. This stage is to ensure the vaccine's safety and to determine the appropriate dosage.
3. Clinical Trials
This stage involves testing the vaccine on humans. It is usually conducted in three phases:
Phase I
: The vaccine is tested on a small group of healthy volunteers to assess its
safety and dosage.
Phase II
: The vaccine is given to a larger group of people to further assess its safety
and efficacy.
Phase III
: The vaccine is administered to thousands of people to confirm its
effectiveness, monitor side effects, and compare it with commonly used treatments.
4. Regulatory Review and Approval
Once the vaccine has passed all clinical trials, it is submitted to regulatory authorities for
review. If approved, the vaccine can be manufactured and distributed.
5. Manufacturing
This stage involves the large-scale production of the vaccine. It must be done in accordance
with strict quality control standards to ensure the safety and efficacy of the vaccine.
6. Quality Control
Even after the vaccine is manufactured, it undergoes continuous quality control checks. This
is to ensure that every batch of the vaccine meets the required standards.
7. Distribution and Post-Marketing Surveillance
Once the vaccine is distributed, post-marketing surveillance is conducted to monitor the
vaccine's performance in real-world conditions and to detect any adverse events.
In the case of bOPV, these stages were crucial in ensuring the vaccine's success in combating
polio.
4.How did the World Health Organization (WHO) coordinate the accelerated clinical trial and
production of bOPV? Why was India selected as the location for the clinical trial? Why was
the clinical trial able to bypass phase I and II? Why and how did the WHO engage drug
manufacturers and national regulatory authorities ?
A.
WHO's Coordination for Accelerated Clinical Trial and Production of bOPV
The World Health Organization (WHO) coordinated the accelerated clinical trial and
production of bivalent oral polio vaccine (bOPV) through a series of strategic steps:
1.
Engagement with Drug Manufacturers and National Regulatory Authorities:
WHO engaged with drug manufacturers and national regulatory authorities to ensure
the production and regulation of the vaccine. This was done through regular meetings,
consultations, and collaborations. The aim was to ensure that the vaccine was
produced in sufficient quantities and met the necessary safety and efficacy standards.
2.
Fast-Track Procedures:
WHO implemented fast-track procedures to accelerate the
clinical trial and production of bOPV. This included bypassing Phase I and II of the
clinical trials, which are typically used to assess the safety and dosage of a new drug
or vaccine. This was possible due to the existing knowledge and data on the safety
and efficacy of the monovalent oral polio vaccines (mOPVs) from which bOPV was
derived.
India was selected as the location for the clinical trial due to several reasons:
High Burden of Polio:
At the time, India had a high burden of polio, which made it a
suitable location for testing the efficacy of the new vaccine.
Existing Infrastructure:
India had an existing infrastructure for polio vaccination
and surveillance, which facilitated the implementation of the clinical trial.
Government Support:
The Indian government was supportive of the trial, providing
necessary approvals and support.
WHO engaged with drug manufacturers and national regulatory authorities in several ways:
Collaboration:
WHO collaborated with these entities to ensure the production and
regulation of the vaccine.
Guidance:
WHO provided guidance on the necessary standards for the production
and regulation of the vaccine.
Monitoring:
WHO monitored the production and regulation processes to ensure
compliance with international standards.
In conclusion, the WHO's strategic coordination and engagement with key stakeholders
played a crucial role in the accelerated clinical trial and production of bOPV.
5.Based on what you’ve learned about reimbursement in Week 11 of the coursehow would
manufacturers go about determining a fair price for the vaccines mentioned in this case? How
about a COVID-19 vaccine for which the benefits of utilization outweigh the potential risks
from a safety perspective? If your answers are different why are they different?
A. Determining a Fair Price for Vaccines
Determining a fair price for vaccines, including a COVID-19 vaccine, involves several
factors. These include the cost of production, research and development expenses, the value
of the vaccine in terms of health benefits, and market demand.
Cost of Production and Research & Development
The first step in pricing a vaccine is to consider the costs associated with its production and
development. This includes:
The cost of raw materials and manufacturing
The cost of research and development
The cost of clinical trials and regulatory approval
For example, if a vaccine costs $100 to produce and the manufacturer spent $1 billion on
research and development, these costs would need to be factored into the price.
Health Benefits and Market Demand
The next step is to consider the health benefits of the vaccine and the demand for it. If a
vaccine prevents a serious disease and there is high demand for it, the manufacturer may be
able to charge a higher price.
For example, a COVID-19 vaccine that is highly effective at preventing the disease and has
high demand could potentially command a higher price.
Pricing a COVID-19 Vaccine
When it comes to a COVID-19 vaccine, the benefits of utilization clearly outweigh the
potential risks from a safety perspective. This is because the disease is highly contagious and
can be severe or fatal. Therefore, the value of the vaccine in terms of health benefits is very
high.
However, it's important to note that the pricing of a COVID-19 vaccine may also be
influenced by other factors, such as government subsidies or agreements, public pressure for
affordability, and the need for widespread vaccination to achieve herd immunity.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
In conclusion, while the basic principles of vaccine pricing apply to both the vaccines
mentioned in the case and a COVID-19 vaccine, the unique circumstances surrounding the
COVID-19 pandemic may influence the pricing of a COVID-19 vaccine.
6.What can the global health community leverage from this experience that can be utilized
during the current COVID-19 pandemic? Additionally, what other diseases could benefit
from the lessons learned in vaccine development from this case?
A. Lessons from Past Experiences for the COVID-19 Pandemic
The global health community can leverage several lessons from past experiences to tackle the
current COVID-19 pandemic.
1.
Rapid Vaccine Development
: The swift development of vaccines for diseases like
Ebola and H1N1 has shown that it is possible to expedite the usually lengthy process
of vaccine development. This has been applied in the development of COVID-19
vaccines, with several vaccines being developed, tested, and approved for emergency
use within a year of the pandemic's onset.
2.
Global Collaboration
: Past pandemics have highlighted the importance of global
collaboration in sharing resources, information, and expertise. This has been crucial in
the fight against COVID-19, with scientists around the world working together to
understand the virus and develop effective treatments and vaccines.
3.
Public Health Infrastructure
: The importance of robust public health infrastructure,
including surveillance systems, testing capabilities, and healthcare facilities, has been
underscored by past pandemics. These elements have been key in managing the
spread of COVID-19.
4.
Communication and Trust
: Past experiences have shown that clear, consistent
communication and building trust with the public are essential in managing a
pandemic. This is particularly relevant in the context of COVID-19, where
misinformation and vaccine hesitancy have been significant challenges.
Diseases That Could Benefit from Lessons in Vaccine Development
The lessons learned in vaccine development during the COVID-19 pandemic could be
applied to a range of other diseases. These include:
1.
Influenza
: The techniques used in the development of mRNA vaccines for COVID-
19 could potentially be applied to create more effective influenza vaccines.
2.
HIV
: The global collaboration and rapid vaccine development seen during the
COVID-19 pandemic could provide a model for renewed efforts to develop a vaccine
for HIV.
3.
Tuberculosis
: The TB vaccine is relatively old and not entirely effective. The lessons
learned from COVID-19 vaccine development could potentially be applied to create a
more effective TB vaccine.
4.
Emerging Infectious Diseases
: The experience of rapidly developing a vaccine in
response to a new disease could be invaluable in responding to future emerging
infectious diseases.
References :
1 . Rosenberg J, Weintraub R.
Chasing Polio Eradication: Vaccine Development
. Harvard
Business Publishing. 2019.